Atossa Therapeutics
ATOS
19 hedge funds and large institutions have $1.51M invested in Atossa Therapeutics in 2020 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 8 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
90% more call options, than puts
Call options by funds: $91K | Put options by funds: $48K
0.23% less ownership
Funds ownership: 0.47% → 0.24% (-0.23%)
16% less capital invested
Capital invested by funds: $1.79M → $1.51M (-$279K)
17% less funds holding
Funds holding: 23 → 19 (-4)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$646K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$477K |
| 3 |
VF
Virtu Financial
New York
|
+$425K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$87K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$29.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$203K |
| 2 |
Two Sigma Investments
New York
|
-$102K |
| 3 |
Goldman Sachs
New York
|
-$52K |
| 4 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$41K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$29K |
ATOS Hedge Fund Activity: Q4 2020 in Review
19 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q4 2020, worth a combined $1.51M — down 16% from $1.79M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ATOS and 4 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 6 added.
The largest buyer was Renaissance Technologies, adding an estimated $646K. The largest seller was Morgan Stanley, cutting an estimated $203K.
- 19 institutional investors held Atossa Therapeutics (ATOS) as of Q4 2020, down from 23 in Q3 2020.
- Funds reported $1.51M of Atossa Therapeutics stock for Q4 2020, down 16% quarter-over-quarter.
- 4 funds opened new Atossa Therapeutics positions in Q4 2020 and 8 closed out, a net change of -4 holders.
- The largest Atossa Therapeutics buyer in Q4 2020 was Renaissance Technologies, an estimated $646K added.
- The largest Atossa Therapeutics seller in Q4 2020 was Morgan Stanley, an estimated $203K sold.
Based on aggregated 13F filings for Q4 2020.